Immunotherapies using anti-CTLA4 and anti-PD1 monoclonal antibodies offer durable long-term survival benefits that were not previously achieved with traditional cytokine immunotherapy and chemotherapy in melanoma and other malignancies [21]. Here, CTLA4 is linked to melanoma.